Differential association between metabolic syndrome and coronary artery disease evaluated with cardiac computed tomography according to the presence of diabetes in a symptomatic Korean population by 김영진 et al.
Won et al. BMC Cardiovascular Disorders 2014, 14:105
http://www.biomedcentral.com/1471-2261/14/105RESEARCH ARTICLE Open AccessDifferential association between metabolic
syndrome and coronary artery disease evaluated
with cardiac computed tomography according to
the presence of diabetes in a symptomatic
Korean population
Ki-Bum Won1,2, Hyuk-Jae Chang1,5,6*, Jimin Sung3, Sanghoon Shin1, In-Jeong Cho1, Chi-Young Shim1,
Geu-Ru Hong1, Young Jin Kim4, Byung-Wook Choi4 and Namsik Chung1Abstract
Background: Metabolic syndrome (MetS) is associated with increased risks of diabetes and coronary artery disease
(CAD). Despite the controversial inclusion of established diabetes in MetS, the association between MetS and CAD
according to diabetes status has not been elucidated in the Asian population.
Methods: We evaluated the association between MetS and CAD using the parameters including any plaque,
obstructive plaque, and coronary artery calcium score (CACS) >100 according to diabetes status in 2,869
symptomatic Korean subjects who underwent cardiac computed tomographic angiography.
Results: The prevalence of MetS was significantly higher in the diabetic subjects than in the non-diabetic subjects
(69% vs. 34%, P <0.001). The incidence of any plaque (64% vs. 43%, P <0.001), obstructive plaque (26% vs. 13%, P = 0.006),
and CACS >100 (23% vs. 12%, P = 0.012) was significantly higher in diabetic subjects than in non-diabetic subjects.
Among the MetS components, decreased high-density lipoprotein level was significantly associated with any
plaque (odds ratio [OR] 1.35), obstructive plaque (OR 1.55), and CACS >100 (OR 1.57) in the non-diabetic subjects
(P <0.01, respectively). However, none of the MetS components were associated with all the parameters in the
diabetic subjects. Multivariate regression analysis revealed that MetS and the number of MetS components (MetSN)
were independently associated with any plaque (MetS: OR 1.55, P <0.001; MetSN: OR 1.22, P <0.001), obstructive
plaque (MetS: OR 1.52, P = 0.003; MetSN: OR 1.25, P <0.001), and CACS >100 (MetS: OR 1.46, P = 0.015; MetSN: OR
1.21, P = 0.004) only in the non-diabetic subjects, respectively.
Conclusions: MetS was independently associated with the presence and severity of CAD only in the non-diabetic
subjects among the symptomatic Korean population.
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Metabolic syndrome (MetS) is a clustering condition of
several cardiovascular (CV) risk factors, and it represents
insulin resistance as a major characteristic [1]. MetS is as-
sociated with the development of coronary artery disease
(CAD) and increased risk of CV morbidity and mortality
[2]. MetS also increases the risk of diabetes development
because its components represent major risk factors for im-
paired glucose metabolism [3]. Accordingly, MetS has been
promoted as a means for identifying the risk of diabetes de-
velopment in clinical practice. Recently, it has been strongly
recommended that conditions with established diabetes
should be excluded from the definition of MS [4]. However,
data supporting this recommendation are limited, especially
regarding coronary atherosclerosis.
A previous study reported that the prevalence of coro-
nary heart disease (CHD) was significantly higher in dia-
betic subjects with MetS than in those without MetS [2].
However, this study defined CHD with only self-reported
myocardial infarction or a positive response to the angina
pectoris section of the Rose Questionnaire without an im-
aging approach for evaluating coronary atherosclerosis [5].
Accordingly, this study might underestimate the prevalence
of CHD. In addition, this study was performed only in a
Western (U.S) population, including African Americans
and Mexican Americans.
Diabetes is a chronic, complex, and progressive illness
that requires persistent medical care to prevent major
CV complications. Diabetes significantly influences the
development of CAD, and most diabetic subjects have
MetS, which represents a major phenotype of insulin re-
sistance. Although deterioration of insulin secretion and
aggravation of insulin resistance are two major defects
in the pathogenesis of diabetes [6,7], the clinical features
of type 2 diabetes cases in Asia are explicitly different
from those of type 2 diabetes cases in other parts of the
world [8]. Several recent studies have reported that im-
paired insulin secretion was more prominent than insulin
resistance, even in the status of impaired glucose tolerance,
in Asian subjects [9,10]. Considering that MetS represents
insulin resistance as a major characteristic, the impact
of MetS on coronary atherosclerosis in diabetic subjects
may be different in the Asian population compared
with the Western population. However, the association
between MetS, individual MetS components, and coronary
atherosclerosis according to the presence of diabetes is not
elucidated in an Asian population.
Coronary computed tomographic angiography (cCTA)
was recently introduced as a novel noninvasive imaging
approach for evaluating coronary atherosclerosis and for
predicting CAD [11,12]. cCTA has high diagnostic accuracy
in detecting CAD [13,14], and the coronary artery calcium
score (CACS) is known as a good marker of CAD, repre-
senting the degree of atheromatous plaque burden [15,16].In this study, we aim to evaluate the association be-
tween MetS, individual MetS components, and coronary
atherosclerosis according to the presence of diabetes in




This was a cross-sectional study analyzing single-center
data collected from 3,159 consecutive symptomatic
South Korean subjects who underwent cCTA evaluation
with 64-slice multidetector computed tomography (MDCT)
at Yonsei Cardiovascular Hospital between January 2005
and April 2009. All participants were referred for evaluation
of CAD who had at least one of the symptoms, including
typical angina, atypical angina, dyspnea, and excessive fa-
tigue, but were not patients with acute coronary syndrome
who required emergent coronary intervention or surgery.
Subjects who were younger than 30 years (n = 26), or had
an estimated modification of diet in renal disease (MDRD)
glomerular filtration rate (GFR) <60 mL/min/1.73m2
(n = 264) were excluded from the present study according
to the study protocol. As a result, 2,869 participants were
finally included. All patients provided written informed
consent, and ethical approval was obtained from the
Institutional Review Board of Severance Hospital, Yonsei
University Health System.
MDCT protocol
Subjects with an initial heart rate ≥65 beats/min before
MDCT examination received a single oral dose of 50 mg
metoprolol tartrate (Betaloc, Yuhan, Seoul, South Korea)
1 h before CT examination unless beta-adrenergic blocking
agents were contraindicated owing to overt heart failure,
atrioventricular conduction abnormalities, and bronchial
asthma. In patients with atrial fibrillation, patients with a
mean heart rate >100 beats/min received beta-adrenergic
blocking agents orally 1 h before cCTA. If the mean heart
rate remained >100 beats/min at the time of scanning,
we withdraw the scan. A contrast-enhanced volume
data set was acquired with retrospective electrocardio-
gram gating without using tube current modulation to
allow reconstructions during all phases of the cardiac
cycle. In subjects with a mild allergy to the contrast
material such as drug eruption or urticaria, we used a
prophylactic IV steroid. However, we did not allow a
scan for the patients with severe allergic reactions such
as shock or laryngeal edema.
Imaging was performed for all the subjects using a
64-slice CT scanner (Sensation 64; Siemens Medical
System, Forchheim, Germany). All CT examinations
were performed during breath holding in inspiration.
Initially, a non-enhanced prospective electrocardiogram-
gated scan to evaluate CACS was performed with the
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collimation of 0.6 mm, slice width of 3.0 mm, tube voltage
of 100–120 kV, tube current of 50 mA, and table feed/scan
of 18 mm. Thereafter, cCTA was performed using retro-
spective electrocardiographic gating with the following scan
parameters: rotation time of 330 ms, slice collimation of
64 × 0.6 mm, tube voltage of 100–120 kV, tube current of
400–800 mA (depending on patient size), table feed/scan of
3.8 mm, and pitch factor of 0.2. ECG-based tube current
modulation was applied to 65% of the R–R interval. A
real-time bolus-tracking technique was applied to trigger
scan initiation. The total estimated average radiation
dose for the multislice CT protocol was 8.8 ± 1.6 mSv.
Contrast enhancement was achieved with 60 mL iopamidol
(370 mg/mL iodine, Iopamiro; Bracco, Milan, Italy) injected
at 5 mL/s, followed by an injection of 30 mL of diluted
contrast medium (saline-to-contrast agent ratio, 7:3)
and then 30 mL saline at 5 mL/s, with a power injector
(Envision CT; Medrad, Indianola, PA) via an antecubital
vein. The estimated volume CT dose index (CTDIvol)
was recorded for each patient. The product of CTDIvol
and scanning length (dose–length product, mGy × cm)
was calculated, and effective dose was estimated using
a normalization factor for the adult chest (0.017 mSv ×
mGy−1 × cm−1). Image reconstruction was performed
in the scanner workstation using commercially available
software (Wizard, Siemens Medical Solutions). Axial im-
ages were reconstructed retrospectively at 65% of the R–R
interval for each cardiac cycle. If artifacts were present,
additional data sets were obtained for various points of
the cardiac cycle, and the data set with the minimum
artifact was selected for further analysis. The reconstructed
image data sets were transferred to an off-line workstation
(Aquar-ius Workstation, TeraRecon, Inc., San Mateo, CA).
Each lesion identified was examined using maximum inten-
sity projection and multiplanar reconstruction techniques
on a short axis and along multiple longitudinal axes.
Lesions were classified by the maximal stenosis of lu-
minal diameter observed on any plane.
Measurement of coronary parameters
All cCTA were evaluated by 2 experienced cardiac radiolo-
gists (Y.J.K. and B.W.C., who respectively had 6 and 9 years
of experience in cardiac CT). In case of disagreement, a
joint reading was performed to reach a consensus. This
study primarily evaluated the presence of any plaque,
obstructive plaque, and a CACS >100. Both any plaque
and obstructive plaque were divided into 2 subtypes ac-
cording to the presence of coronary calcification as follows:
calcified or mixed plaque (CMP) and non-calcified plaque
(NCP). CACS was measured with the scoring system using
a previously described method [17]. Because the frequency
of CACS >100 in the Asian population is known to be low
compared with that in Caucasians, African-Americans, andHispanics [18], and few subjects had a CACS >400 (5%) in
the present study, consequently, we used CACS >100 as
the parameter for estimating severe coronary calcification.
Plaque was defined as structures >1 mm2 within and/or
adjacent to the vessel lumen that were clearly distinguished
from the lumen and surrounding pericardial tissue; ob-
structive plaque was defined as plaque with ≥50% luminal
diameter stenosis. CAD was defined as the presence of any
coronary plaque identified in cCTA (both non-obstructive
and obstructive lesions, including non-calcified plaques).
Measurement of biochemical and clinical parameters
Information on medical history of hypertension, diabetes,
and smoking status were systematically collected. Height,
weight, and blood pressure were measured during hospital
visits. All blood samples were obtained after a minimum
8-h fast and analyzed for triglycerides, high-density lipo-
protein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, and glucose levels. Body mass index (BMI)
was calculated as weight (kg) ÷ height (m2), and obesity
was defined as a BMI ≥25 kg/m2. Kidney function was
assessed based on the estimated GFR calculated using
the formula validated in the Modification of Diet in
Renal Disease study [19]. Current smoking history was
considered present if the subject consistently smoked
or smoked within 1 month before the study. MetS was
defined as the presence of ≥3 of the following: (a) blood
pressure ≥130 mmHg systolic or ≥85 mmHg diastolic,
or on antihypertensive treatment; (b) HDL cholesterol
level <40 mg/dL in men or <50 mg/dL in women; (c)
fasting triglycerides level ≥150 mg/dL; (d) BMI ≥25 kg/m2;
and (e) impaired fasting glucose, defined as a fasting
glucose level ≥100 mg/dL, a referral diagnosis of dia-
betes, or diabetes treatment according to the National
Cholesterol Education Program–Adult Treatment Panel
III definition [1]. Diabetes was defined as a fasting glucose
level ≥126 mg/dL, undergoing an antidiabetic treatment,
or a referral diagnosis of diabetes.
Statistical analysis
Clinical, biochemical, and coronary characteristics are
described according to the presence of MetS and diabetes.
Values are expressed as mean ± SD or n (%). Continuous
variables were compared using the Student t-test, and
categorical variables were compared using the χ2 test.
The associations between the individual MetS compo-
nents and the coronary parameters, namely plaque, ob-
structive plaque, and CACS >100, were analyzed in the
subjects with and without diabetes after adjusting for
confounding risk factors. Univariate and multivariate
logistic regression analyses for identifying the association
between MetS and coronary parameters were performed
according to diabetes status. These analyses were also per-
formed to identify the association between the increase in
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parameters according to diabetes status. The covariate-
adjusted odds ratios (OR) and 95% confidence intervals
(CI) for each coronary parameter were calculated.
Statistical Package for the Social Sciences version 18
(SPSS Inc., Chicago, IL) was used for all the analyses.




The clinical characteristics of the 2,869 subjects (58 ± 9
years, 51% male) are listed in Table 1. Of the subjects, 2,308
were non-diabetic subjects (80%) and 561 were diabetic
subjects (20%). The prevalence of MetS was significantly
higher in the diabetic subjects than in the non-diabetic sub-
jects (69% vs. 34%, P <0.001). The incidence of any plaqueTable 1 Baseline characteristics
Characteristics No diabetes
Total No MetS M
(n = 2,308) (n = 1,515) (
Subjects
Age (years) 57 ± 9 57 ± 9 5
Men, n (%) 1,155 (50) 749 (49) 4
Body mass index (kg/m2) 24.4 ± 2.8 23.6 ± 2.6 2
Current smoking, n (%) 277 (12) 176 (12) 1
SBP (mmHg) 126 ± 15 124 ± 14 1
DBP (mmHg) 79 ± 10 78 ± 9 8
Antihypertensive treatment, n (%) 1,098 (49) 628 (43) 4
Total cholesterol (mg/dL) 188 ± 35 187 ± 34 1
Triglyceride (mg/dL) 140 ± 91 115 ± 61 1
HDL cholesterol (mg/dL) 51 ± 12 54 ± 12 4
LDL cholesterol (mg/dL) 120 ± 33 120 ± 32 1
Creatinine (mg/dL) 0.90 ± 0.16 0.90 ± 0.16 0
GFR (mL/min/1.73 m2) 82 ± 13 82 ± 13 8
FBS (mg/dL) 95 ± 10 93 ± 9 1
Duration of diabetes (years) - - -
Anti-diabetic treatment, n (%) - - -
Coronary atherosclerosis parameters, n (%)
Any plaque 981 (43) 597 (26) 3
CMP 797 (35) 480 (32) 3
NCP 184 (8) 117 (8) 6
Obstructive plaque 292 (13) 171 (11) 1
Obstructive CMP 244 (11) 140 (9) 1
Obstructive NCP 48 (2) 31 (2) 1
CACS≥ 100 264 (12) 155 (10) 1
Data are expressed as n (%) or mean ± SD. CACS, coronary artery calcium score; CA
pressure; FBS, fasting blood sugar; GFR, glomerular filtration rate; HDL, high-density
non-calcified plaque; SBP, systolic blood pressure. *P <0.001 vs. no diabetes. †P <0.0(64% vs. 43%, P <0.001), obstructive plaque (26% vs. 13%,
P = 0.006), and CACS >100 (23% vs. 12%, P = 0.012) was
also significantly higher in diabetic subjects than in non-
diabetic subjects (Figure 1). The incidence of any plaque
(48% vs. 39%, P <0.001), obstructive plaque (15% vs. 11%,
P = 0.006), and CACS >100 (14% vs. 10%, P = 0.012), was
significantly higher in the non-diabetic subjects with MetS
than in those without MetS. However, the incidence of all
these parameters was not significantly different in the dia-
betic subjects according to the presence of MetS (Figure 2).
Association individual MetS component and coronary
parameters according to diabetes status
The association between the individual MetS components
and the coronary parameters according to the presence
of diabetes is presented in Table 2. After adjusting for
age, sex, current smoking status, LDL, and GFR, obesityP Type 2 diabetes P
etS Total No MetS MetS
n = 793) (n = 561) (n = 176) (n = 385)
7 ± 9 0.526 60 ± 9* 61 ± 9 60 ± 8 0.219
06 (51) 0.430 313 (56)† 105 (60) 208 (54) 0.234
5.9 ± 2.5 <0.001 25.0 ± 3.0* 23.1 ± 2.3 25.9 ± 3.0 <0.001
01 (13) 0.500 76 (14) 23 (14) 53 (14) 0.876
30 ± 15 <0.001 128 ± 15† 123 ± 13 130 ± 16 <0.001
1 ± 10 <0.001 78 ± 10 76 ± 9 79 ± 10 <0.001
70 (61) <0.001 298 (54)† 61 (36) 237 (63) <0.001
90 ± 37 0.047 181 ± 37* 176 ± 36 183 ± 38 0.045
90 ± 114 <0.001 160 ± 102* 105 ± 50 185 ± 109 <0.001
5 ± 10 <0.001 48 ± 11* 54 ± 11 46 ± 10 <0.001
20 ± 34 0.850 114 ± 38* 115 ± 42 114 ± 36 0.670
.91 ± 0.16 0.182 0.91 ± 0.16 0.91 ± 0.17 0.90 ± 0.16 0.779
2 ± 13 0.235 83 ± 14 83 ± 14 82 ± 14 0.513
00 ± 11 <0.001 135 ± 43* 133 ± 42 135 ± 44 0.584
- 11 ± 7 12 ± 7 10 ± 7 0.094
- 433 (77) 133 (76) 300 (78) 0.588
84 (48) <0.001 359 (64)* 104 (59) 255 (66) 0.108
17 (40) <0.001 311 (55)* 96 (55) 215 (56) 0.784
7 (8) 0.571 48 (9) 8 (5) 40 (10) 0.022
21 (15) 0.007 145 (26)* 44 (25) 101 (26) 0.835
04 (13) 0.005 122 (22)* 39 (22) 83 (22) 0.912
7 (2) 0.876 23 (4)† 5 (3) 18 (5) 0.366
09 (14) 0.013 129 (23)* 41 (23) 88 (23) 0.946
D, coronary artery disease; CMP, calcified or mixed plaque; DBP, diastolic blood
lipoprotein; LDL, low-density lipoprotein; MetS, metabolic syndrome; NCP,
5 vs. no diabetes.
Figure 1 Comparison of the incidence of coronary parameters
according to diabetes status.
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95% CI 1.05–1.55, P = 0.016). Increased blood pressure
and increased triglycerides were significantly associated
with any plaque (increased blood pressure: OR 1.25,
95% CI 1.01–1.55, P = 0.045; increased triglycerides:
OR 1.37, 95% CI 1.12–1.68, P = 0.002) and obstructive
plaque (increased blood pressure: OR 1.59, 95% CI
1.14–2.23, P = 0.006; increased triglycerides: OR 1.56,
95% CI 1.18–2.06, P = 0.002). Decreased HDL level was
significantly associated with any plaque (OR 1.35, 95% CI
1.09–1.68, P = 0.007), obstructive plaque (OR 1.55, 95%
CI 1.14–2.10, P = 0.005), and CACS >100 (OR 1.57, 95% CI
1.12–2.19, P = 0.008) in the non-diabetic subjects. However,
no MetS components were significantly associated with all
the coronary parameters in the diabetic subjects.
Association between MetS, MetSN, and coronary
parameters according to diabetes status
The association between MetS, the MetSN, and the coron-
ary parameters, including any plaque, obstructive plaque,
and CACS >100 according to the presence of diabetes are
presented in Table 3. The univariate logistic regression ana-
lysis revealed that MetS was significantly associated with in-
creased risks of all coronary parameters in the non-diabeticFigure 2 Comparison of the incidence of coronary parameters accordsubjects (any plaque: OR 1.44, 95% CI 1.21–1.72, P <0.001;
obstructive plaque: OR 1.42, 95% CI 1.10–1.82, P = 0.007;
CACS >100: OR 1.40, 95% CI 1.08–1.82, P = 0.012).
However, MetS was not significantly associated with
any of these parameters in the diabetic subjects. The
MetSN was significantly associated with increased
risks of all coronary parameters in the non-diabetic
subjects (any plaque: OR 1.19, 95% CI 1.11–1.28, P <0.001;
obstructive plaque: OR 1.22, 95% CI 1.10–1.35, P <0.001;
CACS >100: OR 1.18, 95% CI 1.06–1.32, P = 0.002) but not
in the diabetic subjects. After adjusting for age, sex, current
smoking status, LDL, and GFR, MetS was significantly as-
sociated with increased risks of all the coronary parame-
ters in the non-diabetic subjects (any plaque: OR 1.55,
95% CI 1.27–1.89, P <0.001; obstructive plaque: OR 1.52,
95% CI 1.15–2.01, P = 0.003; CACS >100: OR 1.46, 95% CI
1.08–1.99, P = 0.015). However, MetS was not significantly
associated with any of these parameters in the diabetic
subjects. The MetSN was significantly associated with
increased risks of all the coronary parameters in the non-
diabetic subjects (any plaque: OR 1.22, 95% CI 1.12–1.32,
P <0.001; obstructive plaque: OR 1.25, 95% CI 1.11–1.41,
P <0.001; CACS >100: OR 1.21, 95% CI 1.06–1.37, P = 0.004)
but not in the diabetic subjects (Figure 3).
Discussion
To the best of our knowledge, these are the first findings
on the differential association between MetS and CAD
according to diabetes status in a symptomatic Asian
population. We identified that both MetS and MetSN
were independently associated with the presence of
plaque, obstructive plaque, and CACS >100 in the sub-
jects without established diabetes. However, despite the
significantly higher incidence of all the coronary param-
eters in the diabetic subjects than in the non-diabetic
subjects, MetS, the individual MetS components, and
the MetSN were not significantly associated with all
these parameters in diabetic subjects.ing to MetS status. (A) Non-diabetes and (B) diabetes.
Table 3 Association between MetS, MetSN, and coronary parameters according to diabetes status
Any plaque Obstructive plaque CACS >100
Univariate Multivariate Univariate Multivariate Univariate Multivariate
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
No diabetes
MetS 1.44 1.21–1.72* 1.55 1.27–1.89* 1.42 1.10–1.82† 1.52 1.15–2.01† 1.40 1.08–1.82‡ 1.46 1.08–1.99‡
MetSN 1.19 1.11–1.28* 1.22 1.12–1.32* 1.22 1.10–1.35* 1.25 1.11–1.41* 1.18 1.06–1.32† 1.21 1.06–1.37†
Diabetes
MetS 1.36 0.94–1.96 1.38 0.90–2.12 1.07 0.71–1.61 0.98 0.63–1.52 0.99 0.65–1.50 1.10 0.69–1.77
MetSN 1.06 0.89–1.25 1.11 0.92–1.35 1.01 0.84–1.21 0.99 0.81–1.21 0.94 0.78–1.14 1.05 0.85–1.30
CACS, coronary artery calcium score; CI, confidence intervals; LDL, low-density lipoprotein; MetS, metabolic syndrome; MetSN, number of metabolic syndrome
components; OR, odd ratios.
Multivariate models are adjusted for age, sex, current smoking, LDL, and GFR. *P <0.001; †P <0.01; ‡P <0.05
Table 2 Association between individual MetS component and coronary parameters according to diabetes status
Characteristic n Any plaque Obstructive plaque CACS >100
OR (95% CI) OR (95% CI) OR (95% CI)
No diabetes 2308
Obesity
No 1383 1.00 1.00 1.00
Yes 925 1.27 (1.05–1.55) ‡ 1.20 (0.91–1.59) 1.19 (0.88–1.62)
Increased blood pressure
No 664 1.00 1.00 1.00
Yes 1644 1.25 (1.01–1.55)‡ 1.59 (1.14–2.23)† 1.27 (0.89–1.81)
Increased triglycerides
No 1522 1.00 1.00 1.00
Yes 786 1.37 (1.12–1.68)† 1.56 (1.18–2.06)† 1.18 (0.87–1.62)
Decreased HDL
No 1616 1.00 1.00 1.00
Yes 692 1.35 (1.09–1.68)† 1.55 (1.14–2.10)† 1.57 (1.12–2.19)†
Increased fasting glucose
No 1640 1.00 1.00 1.00
Yes 668 1.22 (0.99–1.50) 0.97 (0.72–1.31) 1.24 (0.90–1.69)
Type 2 diabetes 561
Obesity
No 288 1.00 1.00 1.00
Yes 273 1.27 (0.85–1.90) 0.86 (0.57–1.31) 1.12 (0.72–1.75)
Increased blood pressure
No 140 1.00 1.00 1.00
Yes 421 1.03 (0.65–1.63) 0.76 (0.48–1.21) 1.11 (0.66–1.86)
Increased triglycerides
No 315 1.00 1.00 1.00
Yes 246 1.34 (0.89–2.02) 1.00 (0.65–1.53) 0.93 (0.59–1.47)
Decreased HDL
No 347 1.00 1.00 1.00
Yes 214 0.92 (0.60–1.40) 1.44 (0.93–2.24) 1.13 (0.70–1.82)
All models are adjusted for age, sex, current smoking, LDL, and GFR. CACS, coronary artery calcium score; CI, confidence intervals; GFR, glomerular filtration rate;
HDL, high-density lipoprotein; LDL, low-density lipoprotein, MetS, metabolic syndrome; OR, odds ratios. *P <0.001; †P <0.01; ‡P <0.05.
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Figure 3 Impact of MetS and MetSN on the coronary parameters (multivariate analysis). (A) Non-diabetes and (B) diabetes.
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[20,21], and is affecting approximately 31% of adults in
South Korea [22]. MetS and diabetes share many common
characteristics, and 65–85% of diabetic patients have MetS
[23,24]. Despite the similarities, MetS is considered as a
pre-morbid condition rather than a clinical diagnosis
and has been promoted as a means of identifying the risk
of diabetes development [25]. However, most definitions of
MetS simultaneously include diabetes in the diagnostic
criteria as a component of impaired fasting glucose. The
World Health Organization (WHO) strongly recommends
that the conditions of established diabetes or CV disease
should be excluded from MetS [4], but data supporting
this recommendation are limited.
Previous studies have reported that the progression of
atherosclerosis is independently associated with long-term
hyperglycemia in patients with established diabetes [26,27].
Recently, Church et al. [28] reported that the presence
of diabetes in the Aerobics Center Longitudinal Study
was associated with a threefold greater mortality risk
from CV disease and that MetS status did not modify
this risk. Won et al. [29] reported that MetS was signifi-
cantly associated with subclinical atherosclerosis, which
is evaluated with brachial-ankle pulse wave velocity and
carotid intima-media thickness and plaque, in conditions
without diabetes and that a concurrent diagnosis of MetS
might be of little value for predicting subclinical athero-
sclerosis in diabetic subjects. These results suggest the
clinical usefulness of MetS for CV risk stratification only
in subjects without established diabetes. Although MetS
and diabetes are associated with an increased risk of major
CV events, recent studies have suggested that people with
these conditions face a wide range of increased risks ofCV events and that coronary artery calcium is a good
parameter for predicting CV events in people with
MetS and diabetes [30-32]. Although these studies identi-
fied the strong influence of MetS and diabetes on coronary
calcification, they did not evaluate the differential impact of
MetS on coronary calcification according to diabetes status.
Moreover, there is a paucity of data on the association
between MetS and coronary plaque according to the
presence of diabetes. The present study identified the
different association between MetS and coronary athero-
sclerosis according to diabetes status. MetS was independ-
ently associated with any plaque, obstructive plaque, and
CACS >100 only in the non-diabetic subjects after adjust-
ing for confounding risk factors. In addition, although the
incidence of these coronary parameters tended to increase
according to the increase of MetSN in all participants
(Additional file 1: Table S1), the MetSN was also independ-
ently associated with these coronary parameters only in the
non-diabetic subjects. These results suggest that the pro-
gression of coronary atherosclerosis may be influenced by
multiple metabolic risk factors in non-diabetic subjects but
may be predominantly dependent on long-term hypergly-
cemia in subjects with established diabetes status [26,27].
The present study evaluated the association between the
individual MetS component and coronary atherosclerosis
according to the presence of diabetes. Among all the
coronary atherosclerotic parameters, the identification
of obstructive plaque might be the most important be-
cause this study was performed in symptomatic subjects.
Although the measurement of CACS was not recom-
mended in symptomatic subjects, the incidence of obstruct-
ive plaque was similar with that of CACS >100 in both the
non-diabetic and diabetic subjects among the symptomatic
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increased blood pressure, increased triglycerides level, and
decreased HDL level were independently associated with
obstructive plaque in the non-diabetic subjects, but no
MetS components were associated with obstructive plaque
in the diabetic subjects. In the multivariate regression ana-
lysis for identifying the association between the individual
MetS component and subtypes of obstructive plaque
according to diabetes status, increased blood pressure,
increased triglycerides level, and decreased HDL level
were associated with obstructive CMP, not obstructive
NCP, in the non-diabetic subjects. However, none of
MetS components were associated with either obstruc-
tive CMP or obstructive NCP in the diabetic subjects
(Additional file 2: Table S2). In the present study, we
could not evaluate the association between impaired
fasting glucose and obstructive plaque in the diabetic
subjects because all of them had impaired fasting glu-
cose. The component of impaired fasting glucose was
unable to reflect differences in degree of hyperglycemic
control, diabetes duration, and diabetes treatment in the
diabetic subjects. Considering the significantly higher
incidence of obstructive plaque in diabetic subjects than in
non-diabetic subjects, these factors might be more closely
related to obstructive plaque compared with the other
MetS components in an established diabetic condition.
The present study has some limitations. First, we did
not involve asymptomatic subjects in the present study.
However, the application of cCTA for CV risk stratifica-
tion in asymptomatic or low CV risk subjects has not been
justified [33]. Second, we could not eliminate the possible
effects of underlying medication on CAD because of
the observational design of this study. Third, although
we analyzed the association between MetS, individual
MetS components, and plaque subtype, the incidence
of NCP and obstructive NCP was too low to identify
the impact of MetS and its individual component on
these coronary parameters. Lastly, in the present study,
we identified only the differential impact of MetS and
its individual components on CAD, focusing on the
presence of plaque, obstructive plaque, and coronary
calcification, using MDCT according to diabetes status.
Recent CT studies investigating patients with acute coro-
nary syndrome have identified high-risk plaque features
characteristic of culprit lesions, such as low plaque attenu-
ation, positive remodeling, and spotty calcification [34,35].
Further large-scale investigations for identifying the
impact of MetS and diabetes on plaque vulnerability
may be necessary in subjects with suspected CAD.
Despite the several limitations of the present study, it
was unique in that we identified the association between
MetS and CAD according to the diabetic status of the
subjects of Asian ethnicity only. Considering the clinical
features of diabetic subjects in the Asian populationmight be explicitly different compared with those in a
Western population, identification of the impact of MetS
and its individual components on coronary atherosclerosis
according to diabetes status in the Asian population might
be important. The present study identified that MetS and
the MetSN were independently associated with the pres-
ence and severity of CAD only in the non-diabetic subjects,
despite the significant impact of diabetes on CAD in symp-
tomatic Korean subjects. Moreover, this might provide
clinical evidence related to the WHO recommendation that
established diabetes should be excluded from MetS.
Conclusions
In conclusion, MetS was independently associated with the
presence and severity of CAD only in the non-diabetic sub-
jects among the symptomatic Korean population. However,
despite the significantly higher incidence of all the coronary
parameters in the diabetic subjects than in the non-diabetic
subjects, MetS, the individual MetS components, and the
MetSN were not significantly associated with the presence
and severity CAD in the diabetic subjects.
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